None listed
Conditions
Interventions
Intervention1: 1.Dermoviva Baby Olive shampoo â?? DRDC/2019/005
2.Dermoviva Baby Olive Moisturizing Lotion â?? DRDC/2019-006
3.Dermoviva Baby Olive Enriched powder â?? DRDC/2019-007
4.Dermoviva Baby O
Sponsors
Dabur India Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy male and female subjects (1:1 ratio) in the age group of 18-65 years (both age inclusive) with non-sensitive skin 2. Subjects scoring less than or equal to 30 for Section 2- Sensitive v/s Resistant skin in modified Dr. Baumannâ??s skin type questionnaire. Please see detail annexure II 3. Subjects representing with normal, oily, dry and combination skin type in equal ratio. 4. Subjects with normal Fitzpatrick skin type III to V. 5. Female subjects with child bearing potential willing to undergo Urine Pregnancy Test. 5. Subjects free from excessive hair, cuts, wounds, irritation symptoms, abrasion or any other skin condition which may interfere in the study results. 6. Subjects willing to give voluntary written informed consent. 7. Subjects willing to maintain the patch test in position for 24 hours. 8. Subject having not participated in a similar investigation in the past two weeks. 9. Subjects willing to come for regular follow up visits. 10. Subjects ready to follow instructions during the study period.
Exclusion criteria
Exclusion criteria: 1. Infection, allergy on the tested area. 2. Skin allergy antecedents or atopic subjects. 3. Subjects with known hypersensitivity to any of the study products or constituents. 4. Subjects with any significant skin pathology in the investigational area 5. Athletes and subjects with history of excessive sweating. 6. Cutaneous disease which may influence the study result. 7. Subjects using any topical or systemic treatment that could interfere with the study treatments/assessments within the last 4 weeks prior to participation in the study and during the study. 8. Subjects on oral corticosteroid 9. Subjects participating in any other cosmetic or therapeutic study. 10. Female subjects who are pregnant or lactating. 11. Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of Dermatological Safety of Investigational Products By 24 Hours Patch Test Under Complete Occlusion on Adult Healthy Human Subjects with Non-SensitiveTimepoint: 0 hr, 24 hr, 48 hr & 7 days | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactRitambhara
Dabur India Limited
Outcome results
None listed